Rekvina Laboratories Ltd

Rekvina Laboratories Management Change

Rekvina Laboratories Ltd announced a change in its registered office within the city and the resignation of its Managing Director, Mr. Amit Shah.

Rekvina Laboratories Management Change

Mr. Amit Mukesh Shah has resigned as Managing Director and Director of Rekvina Laboratories Limited, effective September 11, 2026.

Rekvina Laboratories Other Announcement

The company filed its shareholding pattern reporting changes in share distribution following the recent open offer. The public shareholding has fallen below the minimum threshold.

Rekvina Laboratories Board Meeting Outcome

Rekvina Laboratories' board meeting approved the Annual Report for FY2025-26 and the notice for the upcoming AGM. It also noted the resignation of the Company Secretary.

Rekvina Laboratories Annual General Meeting

Rekvina Laboratories' 38th AGM will be held online on September 29, 2026. The board also approved the notice and noted the company secretary's resignation.

Rekvina Laboratories Management Change

Mr. Deepak Khandelwal has resigned from his position as Company Secretary and Compliance Officer of Rekvina Laboratories Limited, effective from September 2, 2026.

Rekvina Laboratories Capital Structure Change

Dhruvalkumar Patel acquired 11,12,562 equity shares (10.01% stake) in Rekvina Laboratories Ltd via open offer and preferential allotment. The acquisition increases the investor's significant holding in the company.

Rekvina Laboratories Price Movement Clarification

Rekvina Laboratories Limited clarified that recent stock price movements are market-driven and not due to any undisclosed price-sensitive information or material developments.

Rekvina Laboratories Q1 FY27 Results: Net Loss of ₹0.1 Cr

Rekvina Laboratories Ltd reported revenue from operations of ₹0.7 Cr and a net loss of ₹0.1 Cr for Q1 FY27.

Key figure

Net loss ₹0.1 Cr

Rekvina Laboratories Merger & Restructuring Worth ₹5.09 Cr

Rekvina Laboratories allotted 50,87,750 equity shares on a preferential basis, aggregating ₹5.09 Crore, to acquire Radiant Parenterals Limited as a wholly-owned subsidiary.

Value

₹5.09 Cr